FTC Calls In-House Ilumina Case As Important As Fed. Trial
Federal Trade Commission staffers challenging Illumina's $8 billion plan to buy cancer testing company Grail are eager to get the case moving both in federal court and via the agency's in-house...To view the full article, register now.
Already a subscriber? Click here to view full article